Escalation therapy may be considered for most MS patients, since
more than 80% of them do not have aggressive MS25.
Some DMDs used in this approach are not associated with
increased risk of infection, such as beta- interferons, glatiramer acetate,
and teriflunomide26. Dimethyl fumarate association with increased infection risk was
controversial27. Therefore, they should be preferred for these patients during
the pandemic.